<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343976</url>
  </required_header>
  <id_info>
    <org_study_id>2020P001083</org_study_id>
    <nct_id>NCT04343976</nct_id>
  </id_info>
  <brief_title>Pegylated Interferon Lambda Treatment for COVID-19</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raymond Chung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda
      (180 mcg SC injection) vs.placebo in up to 20 inpatient subjects with COVID-19 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to assess the efficacy of Pegylated Interferon Lambda (180 mcg) vs.
      placebo in inducting quantitative PCR negativity at day 7
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable COVID PCR at day 7</measure>
    <time_frame>1 week</time_frame>
    <description>Negative COVID PCR testing 7 days after first lambda dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Undetectable COVID PCR at day 3, 10 and 14</measure>
    <time_frame>2 weeks</time_frame>
    <description>Negative COVID PCR testing 3, 5, 7 and 14 days after first lambda dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects on Lambda vs placebo with symptomatic improvement</measure>
    <time_frame>2 weeks</time_frame>
    <description>Daily symptom score improvement during treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects on Lambda vs placebo with improved clinical outcomes</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time to event for death, intubation, hospital discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Lambda Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with subcutaneous injection (180 mcg) of pegylated interferon lambda</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection of saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon lambda</intervention_name>
    <description>180 mcg subcutaneous injection of pegylated interferon lambda</description>
    <arm_group_label>Lambda Treatment</arm_group_label>
    <arm_group_label>Saline Placebo</arm_group_label>
    <other_name>Lambda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide informed consent

          -  Admitted to the hospital (MGH) with COVID-19 infection

          -  Confirmed COVID-19 diagnosis based on PCR analysis of respiratory secretions

          -  Positive SARS-CoV-2 RT-PCR test must be within 48 hours of randomization

        Exclusion Criteria:

          -  Clinically-significant illness or any other major medical disorder that in the opinion
             of the investigator, may interfere with subject treatment, assessment or compliance
             with the protocol

          -  Treatment with IFN or other immunomodulatory/immunosuppressive agent within 12 months
             before screening.

          -  Respiratory compromise requiring ventilatory support other than nasal cannula (mask,
             bipap or intubation and mechanical ventilation)

          -  History of treatment with any of the following medications within five half-lives or
             30 days before administration of the study drug (whichever is longer): anti-IL-6,
             anti-IL6R antagonists, Janus kinase inhibitors, ustekinumab (anti-IL-12/23), or anti
             IL-23 agents (guselkumab).

          -  Life threatening SAE during the screening period

          -  Pregnant or Nursing Females

          -  Platelet count &lt;90,000 cells/mm3

          -  WBC count &lt;3,000 cells/mm3

          -  ANC &lt;1,500 cells/mm3

          -  Hb &lt;11 g/dL for women and &lt;12 g/dL for men

          -  CrCl &lt; 50 mL/min

          -  Bilirubin level ≥ 2.5 mg/dL

          -  Alb &lt;3.5 g/dL

          -  INR ≥1.5 (except in the setting of concomitant anticoagulant use)

          -  D-dimer &gt; 1500 ng/mL

          -  CRP &gt; 200 mg/L

          -  Clinically-relevant alcohol or drug abuse within 12 months of screening

          -  Known hypersensitivity to Interferons

          -  Current or planned participation in an investigational new drug (IND) trial from
             30-days prior to randomization through Day 14 post treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond Chung</investigator_full_name>
    <investigator_title>Director of Hepatology, MGH</investigator_title>
  </responsible_party>
  <keyword>COVID</keyword>
  <keyword>Coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Coded data is anticipated to be shared with outside institutions. Safety data will be shared with the drug manufacturer</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data is anticiapted to be made available within 3 months of study completion. Safety data, specifically treatment related adverse events, will be shared in real time</ipd_time_frame>
    <ipd_access_criteria>researchers accessing IPD must be an approved and have a data use agreement in place with Partners Healthcare to access the data</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

